logo
logo
ATEC stock ticker logo

Alphatec Holdings, Inc.

NASDAQ•ATEC
CEO: Mr. Patrick S. Miles
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2006-06-12
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Contact Information
1950 Camino Vida Roble, Carlsbad, CA, 92008, United States
760-431-9286
www.atecspine.com
Market Cap
$1.70B
P/E (TTM)
-11.8
24.3
Dividend Yield
--
52W High
$23.29
52W Low
$8.81
52W Range
17%
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$212.93M+0.00%
4-Quarter Trend

EPS

-$0.15+0.00%
4-Quarter Trend

FCF

$9.57M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenue reached $764.2M in 2025, marking a strong 25% increase fueled by surgeon adoption and portfolio expansion.
Operating Cash Flow Reversal Operating activities provided $45.2M cash, reversing $44.7M cash used during the preceding 2024 fiscal period.
Net Loss Significantly Narrowed Net loss narrowed to $143.4M in 2025, reflecting a favorable improvement of $18.8M compared to the prior year.
Debt Structure Optimized Issued $405.0M 2030 Notes and utilized proceeds to repurchase 80% of outstanding 2026 Convertible Senior Notes.

Risk Factors

Litigation Expense Spike Litigation costs increased 143% to $23.8M, primarily due to a shareholder settlement recorded during the 2025 fiscal year.
Intense Market Competition Operates in highly competitive segment against large, well-capitalized medical device firms with greater resources.
Regulatory Compliance Exposure Subject to extensive FDA regulation; non-compliance risks fines, product recalls, or operational restrictions.
Sales Channel Dependency Business success relies heavily on attracting and retaining qualified independent sales agents for effective market penetration.

Outlook

Compel Surgeon Adoption Focus on
Continue Clinical Innovation Continue investing in next-generation surgical approaches integrated with the expanding InformatiX platform for clinical distinction.
Expand Global Footprint Currently building profitable international footprint in select attractive markets including Australia, New Zealand, and Japan.
R&D Focus on Pathologies Prioritize developing technology platforms addressing major degenerative and deformity spine pathologies for market penetration.

Peer Comparison

Revenue (TTM)

ARDT stock ticker logoARDT
$6.32B
+6.0%
SGRY stock ticker logoSGRY
$3.31B
+6.2%
BKD stock ticker logoBKD
$3.12B
+4.8%

Gross Margin (Latest Quarter)

ARDT stock ticker logoARDT
165.5%
-25.6pp
LQDA stock ticker logoLQDA
101.7%
+29.3pp
IDYA stock ticker logoIDYA
89.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SRRK$5.67B-15.0-145.9%26.9%
CDTX$5.61B-18.6-60.1%0.4%
CELC$5.46B-33.5-203.2%41.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.0%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:Apr 30, 2026
|
EPS:-$0.05
|
Revenue:$197.63M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data